EBS News and Press, Emergent Biosolutions Inc. From 06/11/21

Emergent continues to work with the FDA to address identified observations at Bayview facility in order to release additional batches and resume production GAITHERSBURG, Md., June 11, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that two batch...

Value opportunities appear because of fear, which is reflected in the stock price of the company. Emergent BioSolutions has been hit with negative news, resulting in a crash in recent months. Despite the negative sentiment surrounding the business, their future and valuation appea...

San Francisco, California--(Newsfile Corp. - June 10, 2021) -   Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now . Class Period: Apr. 24, 2020 - Apr. 16, 2021 Lead Plaintiff Deadline: June 18, 2021 Visit: ...

San Francisco, California--(Newsfile Corp. - June 8, 2021) -   Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now . Class Period: Apr. 24, 2020 - Apr. 16, 2021 Lead Plaintiff Deadline: June 18, 2021 Visit: ...

The FDA and Johnson & Johnson (JNJ) are close to an announcement that millions of its doses produced at a troubled Baltimore Emergent BioSolutions (EBS) can be released, according to The Wall Street Journal.The vaccines can be distributed because contamination issues, detailed in an FDA i...

Emergent BioSolutions (EBS) announces two-year data from its Phase 2 clinical study evaluating the safety and immunogenicity of investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in 415 healthy adults.Emergent’s CHIKV VLP vaccine continued to demonstrat...

A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dos...

Documents released this morning as part of a House Select Subcommittee on the Coronavirus Crisis report has found that executives of troubled Emergent BioSolutions (EBS) gave significant sums of money to Washington lawmakers to allegedly cultivate relationships.Emergent's co-founder, Fuad El-...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. For further details see: IYH: Healthcare Dashboard For May

Emergent BioSolutions (EBS) executives are set to testify before the House Select Subcommittee on the Coronavirus on May 11.The beleaguered company is trying to recover from a series of setbacks related to its contract manufacture of COVID-19 vaccine for Johnson & Johnson (JNJ).The meetin...